Lv11
10 积分 2024-03-27 加入
Lung cancer survival in China and world-wide: results from CONCORD-3
7小时前
待确认
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers
7小时前
求助中
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
7小时前
已完结
The blockade of immune checkpoints in cancer immunotherapy
4天前
已完结
Immune-checkpoint inhibitors march on, now in combinations
4天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
12天前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
1个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
1个月前
已完结
Clinical Benefit of Avapritinib in KIT- Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies
1个月前
已完结
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
1个月前
已完结
皖公网安备34019202002308
